Injectable morphine recalled due to overdose risk

Posted on

Hospira Incorporated, a pharmaceutical manufacturer specializing in injectable medications and headquartered in Lake Forest, Illinois, has issued a voluntary recall for a single production lot of injectable morphine sulfate. This recall has been announced at the urging of the United States Food and Drug Administration due to a labeling error that could result in a patient receiving an incorrect dosage of the drug. Hospira Incorporated has received two consumer complaints that its Morphine Sulfate Injection USP, 4 milligram/milliliter (C-II), 1 milliliter fill in 2.5 milliliter Carpuject, NDC 0409-1258-30 syringes contained more than the 1 milliliter volume indicated on the label affixed to product’s packaging. The company currently believes this error to be limited to a single production line. The product is a glass cartridge prefilled with morphine sulfate for use with the Carpucet Syringe system. The consequences of a morphine overdose can be deadly. Symptoms of a morphine overdose include low blood pressure and slowed or suspended breathing patterns, also known as respiratory depression. The lot affected by this recall was distributed to hospitals in several states across the country, including: Indiana, Texas, Colorado, Illinois, Hawaii, Minnesota, Michigan, Ohio, Arizona and Virginia. The production lot number affected by this recall is 10830LL, and morphine cartridges included in this production lt are stamped with the expiration date of April 1, 2013. Consumers seeking more information can call the Hospira Medical Communications hotline, open 7 days a week, 24 hours a day.